Document ID: chunk:federal_register_of_legislation:F2020L00201:clause:1_1:p1
Version: federal_register_of_legislation:F2020L00201
Segment Type: clause
Provision Reference: sch 1 cl 1 (pt 1/2)
Character Range: 9952–14008

1               Definitions
In this instrument:
                                  antiangiogenic agent means a drug that inhibits angiogenesis and is used in cancer therapy.  Examples include, but are not limited to, bevacizumab, sunitinib and thalidomide.
                                  chronic renal failure means:
         (a)          having a glomerular filtration rate of less than 15 mL/min/1.73 m2 for a period of at least three months; or
         (b)          a need for renal replacement therapy (dialysis or transplantation) for treatment of complications of decreased glomerular filtration rate which would otherwise increase the risk of morbidity and mortality; or
         (c)          undergoing chronic dialysis.
                                  dyslipidaemia means persistently abnormal blood lipid levels, diagnosed by a medical practitioner and evidenced by:
         (a)          a total serum cholesterol level greater than 5.5 mmol/L; or
         (b)          a serum low density lipoprotein level greater than 4.0 mmol/L; or
         (c)          a serum high density lipoprotein cholesterol level less than 1.0 mmol/L.
                                   equivalent glucocorticoid therapy means a glucocorticoid in the following table, at the doses specified in the table, or a therapeutically equivalent dose of another glucocorticoid:

 Glucocorticoid      Minimum cumulative  Minimum average
                     dose (milligrams)   rate (milligrams/day)
 betamethasone       475                 1.3
 cortisone           18 250              50
 dexamethasone       585                 1.6
 hydrocortisone      14 600              40
 methylprednisolone  2 920               8
 paramethasone       1 460               4
 prednisone          3 650               10
 triamcinolone       2 920               8

                                   glucocorticoid therapy as specified means:
         (a)           taking prednisolone, orally or by injection:
            (i)            to a cumulative dose of at least 3 650 milligrams; and
            (ii)         at a minimum dose rate averaging 10 milligrams per day; or
         (b)          taking               equivalent glucocorticoid therapy, orally or by injection.
Note:               equivalent glucocorticoid therapy is also defined in the Schedule 1 – Dictionary.
                                  hyperbaric exposure as specified means an increase in the ambient barometric pressure exerted by the envelope of air or water surrounding the person, occurring with:
         (a)          being in a pressurised tunnel or chamber for a continuous period of at least 30 minutes; or
         (b)          being in a submerged craft or device, that is in a hyperbaric state, for a continuous period of at least 30 minutes; or
         (c)          breath-hold diving to a depth of at least five metres and for a duration of at least one minute, on at least ten occasions within a continuous six month period; or
         (d)          compression in a hyperbaric chamber; or
         (e)          underwater diving with compressed air to a depth of at least 15 metres, for a continuous period of at least 30 minutes.
                                  hypercoagulable state as specified means:
         (a)          acquired activated protein C resistance;
         (b)          acquired antithrombin III deficiency;
         (c)          acquired dysfibrinogenaemia;
         (d)          acquired protein C deficiency;
         (e)          acquired protein S deficiency;
         (f)           acquired thrombophilia;
         (g)          antiphospholipid antibody syndrome;
         (h)          disseminated intravascular coagulation;
         (i)            haemolytic uraemic syndrome;
         (j)            heparin-induced thrombocytopaenia;
         (k)          hyperfibrinogenaemia;
         (l)            hyperproteinaemia;
         (m)        hyperviscosity syndrome;
         (n)          immune thrombocytopaenia;
         (o)          nephrotic syndrome;